Actively Recruiting
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Led by Klaus Martiny · Updated on 2026-03-03
60
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
Sponsors
K
Klaus Martiny
Lead Sponsor
T
Technical University of Denmark
Collaborating Sponsor
AI-Summary
What this Trial Is About
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation. In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.
CONDITIONS
Official Title
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between 18 and 75 years old
- Diagnosed with a major depressive episode and currently experiencing depression according to DSM-5
- Major Depression Inventory (MDI) score greater than 21 at screening
- On stable medication and/or psychotherapy for at least 4 weeks before starting the trial
- Willing and able to use the light device for 1 hour daily for 6 weeks
- Able to understand study information and willing to sign informed consent
You will not qualify if you...
- History of photosensitive migraines or epileptic seizures
- Known eye disorders sensitive to light treatment
- History of bipolar disorder according to DSM-5
- Suicidal ideation with a score of 2 or more on HAM-D 17 item 3, or uncertain suicidal risk
- Current psychotic symptoms (except prior or resolved psychotic depression)
- Current drug or alcohol dependence
- History of borderline personality disorder
- Currently enrolled in another investigational treatment study
- Progressive neurodegenerative or cancerous disease
- Unable to understand study procedures or device use
- Pregnant or unsafe contraception in women of fertile age
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mental Health Centre Copenhagen
Copenhagen, Denmark, Denmark, 2100
Actively Recruiting
Research Team
K
Klaus Martiny
CONTACT
M
Malina Ploug Larsen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here